Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
NCT03168100 · University of Arkansas · PHASE2 · withdrawn · last registry update 2019-01-28 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No study population. No subjects enrolled.” | Open Targets' class: insufficient enrollment | Registry record, University of Arkansas |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLAMF7 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-07-17Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, Elotuzumab (NCT03393273)
- 2019-06-03Results posted on the registry: Bristol-Myers Squibb, Elotuzumab + Pomalidomide (NCT02654132)
- 2019-05-13Phase 3 first posted: Wuerzburg University Hospital, Elotuzumab + Carfilzomib (NCT03948035)
- 2018-08-29Phase 3 first posted: Celgene, bb2121 + Daratumumab (NCT03651128)
- 2018-08-14Also stopped (withdrawn): Dana-Farber Cancer Institute, Dexamethasone + Pomalidomide (NCT03227432)
- 2018-05-23Also stopped (terminated): PETHEMA Foundation, Nivolumab + Pomalidomide (NCT03023527)
- 2018-03-22Results posted on the registry: Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT02272803)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision